23.35
price up icon0.56%   0.13
after-market After Hours: 23.35
loading
Celldex Therapeutics Inc stock is traded at $23.35, with a volume of 969.95K. It is up +0.56% in the last 24 hours and up +8.81% over the past month. Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$23.22
Open:
$23.17
24h Volume:
969.95K
Relative Volume:
1.00
Market Cap:
$1.55B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-9.0504
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
+4.19%
1M Performance:
+8.81%
6M Performance:
-2.79%
1Y Performance:
-46.76%
1-Day Range:
Value
$22.52
$23.50
1-Week Range:
Value
$21.71
$24.05
52-Week Range:
Value
$14.40
$47.00

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
Name
Celldex Therapeutics Inc
Name
Phone
908-200-7500
Name
Address
53 FRONTAGE ROAD, HAMPTON
Name
Employee
186
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
CLDX's Discussions on Twitter

Compare CLDX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CLDX
Celldex Therapeutics Inc
23.35 1.54B 9.98M -154.08M -159.66M -2.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-28-25 Initiated Canaccord Genuity Buy
Mar-20-25 Initiated Morgan Stanley Overweight
Feb-13-25 Initiated UBS Buy
Oct-07-24 Initiated Citigroup Buy
Sep-30-24 Initiated Goldman Neutral
Sep-27-24 Downgrade Wolfe Research Outperform → Peer Perform
Jun-18-24 Initiated Stifel Buy
Jun-11-24 Initiated Wolfe Research Outperform
Dec-20-23 Initiated TD Cowen Outperform
Nov-10-23 Upgrade Wells Fargo Underweight → Equal Weight
Aug-22-23 Initiated Wells Fargo Underweight
Sep-17-21 Initiated Jefferies Buy
Sep-10-21 Initiated SVB Leerink Outperform
Jul-22-21 Initiated Guggenheim Buy
Feb-21-20 Initiated Cantor Fitzgerald Overweight
Aug-01-17 Resumed H.C. Wainwright Buy
Nov-07-16 Initiated Aegis Capital Buy
Mar-08-16 Downgrade Jefferies Buy → Hold
Mar-07-16 Downgrade Guggenheim Buy → Neutral
Mar-07-16 Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16 Downgrade Wedbush Outperform → Neutral
Mar-01-16 Initiated H.C. Wainwright Buy
Aug-11-15 Reiterated Brean Capital Buy
Aug-11-15 Reiterated Oppenheimer Outperform
Aug-11-15 Reiterated ROTH Capital Buy
Jun-02-15 Reiterated WBB Securities Strong Buy
Nov-17-14 Reiterated ROTH Capital Buy
Mar-04-14 Reiterated Oppenheimer Outperform
Jul-08-13 Reiterated Cantor Fitzgerald Buy
Mar-08-13 Reiterated Cantor Fitzgerald Buy
Feb-26-13 Reiterated Oppenheimer Outperform
Jan-10-13 Reiterated Cantor Fitzgerald Buy
Oct-02-12 Reiterated Oppenheimer Outperform
Sep-14-12 Reiterated Cantor Fitzgerald Buy
View All

Celldex Therapeutics Inc Stock (CLDX) Latest News

pulisher
Jul 25, 2025

Celldex Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Celldex Therapeutics Inc. stock priceFree Investment Risk Control - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Why Celldex Therapeutics Inc. stock attracts strong analyst attentionFree Trading Group - Newser

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Celldex Therapeutics Inc. stockConsistently superior profits - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Is Celldex Therapeutics Inc. a good long term investmentRapidly expanding wealth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 18, 2025

Is Celldex Therapeutics Inc. stock a good hedge against inflationFree Short-Term Stock Picks - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

What makes Celldex Therapeutics Inc. stock price move sharplySafety First Trading Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Celldex Therapeutics Inc. stock performs during market volatility2x Return Forecast - beatles.ru

Jul 15, 2025
pulisher
Jul 08, 2025

Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Jul 08, 2025
pulisher
Jul 03, 2025

B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, - openPR.com

Jul 03, 2025
pulisher
Jun 27, 2025

Cholera Vaccines Market Deep Research and Growth in Future Scope - openPR.com

Jun 27, 2025
pulisher
Jun 25, 2025

Is Celldex Therapeutics, Inc. technically bullish or bearish? - MarketsMojo

Jun 25, 2025
pulisher
Jun 24, 2025

(06/24/25) CLDX: A Promising Biotech Name Targeting CSU - moneyshow.com

Jun 24, 2025
pulisher
Jun 23, 2025

Chronic spontaneous urticaria improvements persist 28 weeks after barzolvolimab stopped - Healio

Jun 23, 2025
pulisher
Jun 16, 2025

Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Q2 Earnings Estimate for CLDX Issued By Lifesci Capital - Defense World

Jun 16, 2025

Celldex Therapeutics Inc Stock (CLDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):